Scientists Find Different Biological Signatures in Type 1 Diabetes Based on Age of Diagnosis

A large study reveals that children diagnosed with Type 1 diabetes at different ages show distinct differences in their gut bacteria, metabolism, and immune responses. These findings could help researchers better understand why Type 1 diabetes develops differently in different children.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

Type 1 diabetes appears to involve different biological patterns depending on whether a child is diagnosed before age 7, between 7-12 years, or at 13 or older
Researchers identified specific gut bacteria, metabolites, and lipids (fats) that differ between these age groups
Children diagnosed earliest show the highest levels of B cells (immune cells), while those diagnosed later show different immune patterns
These age-related differences suggest Type 1 diabetes may not be a single disease but rather different forms with distinct underlying biology

A New Way to Think About Type 1 Diabetes

Type 1 diabetes doesn't progress the same way in all children. Some develop it very early, others in middle childhood, and some in their teenage years. While doctors have long recognized these age differences, the reasons behind them have remained unclear.

A new study published in *Signal Transduction and Targeted Therapy* took a comprehensive approach to understanding these differences. Researchers analyzed blood and biological samples from 108 newly diagnosed children with Type 1 diabetes and 56 healthy children. They examined four different biological systems: gut microbiota (bacteria), metabolites (chemical byproducts in the body), lipids (fats), and immune gene activity.

Three Different Patterns of Type 1 Diabetes

The researchers divided children into three groups based on age at diagnosis: early-onset (before age 7), intermediate-onset (ages 7-12), and late-onset (age 13 and older). Each group showed distinct biological signatures.

In the gut bacteria, different bacterial species were most prominent in each age group. Children with early-onset Type 1 diabetes had higher levels of a bacterium called Acetatifactor. Those with intermediate-onset Type 1 diabetes showed more Firmicutes A bacteria, while those with late-onset Type 1 diabetes had more Bacteroidaceae. These are significant differences—not just slight variations.

The metabolites (chemical substances the body produces) also differed by age group. For example, pipecolic acid was most elevated in early-onset cases, testosterone in intermediate-onset cases, and N-acetylhomocitrulline in late-onset cases. Similarly, the types of fats circulating in the blood varied by age group.

Immune System Differences Across Age Groups

Perhaps most striking were the differences in immune cells. B cells are white blood cells that play a role in immune responses. Children with early-onset Type 1 diabetes had significantly higher percentages of B cells in their blood (median 11.64%) compared to those with late-onset diabetes (median 5.99%). Those in the intermediate group fell between these values (median 8.47%).

These differences in B cell proportions were linked to different patterns of gene activity. In early-onset cases, genes related to immune function were more active. In late-onset cases, genes related to metabolism were more active instead. This suggests that different biological processes may be driving Type 1 diabetes development at different ages.

What This Means for Future Research

This study suggests that Type 1 diabetes in very young children may involve different biological mechanisms than in older children. The findings point to possible links between specific gut bacteria and immune cell activity, though more research is needed to fully understand these connections.

Understanding these age-related differences could eventually help researchers develop more targeted approaches to studying and possibly preventing Type 1 diabetes. However, this research is in early stages. The findings describe patterns and associations, not yet mechanisms that would lead to new treatments. Much additional work is needed before this knowledge translates to clinical practice.

Evidence label

Source: Signal transduction and targeted therapy. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.